World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
50
Citations
7364
World Ranking
4277
National Ranking
1945

Shixia Wang publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Shixia Wang sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 157 publications — 18th percentile

18% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Shixia Wang D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Shixia Wang sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 50 D-Index — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Shixia Wang is affiliated with the University of Massachusetts Chan Medical School in the United States. Their research primarily spans the fields of immunology and microbiology, with significant contributions to medicine. Within these larger fields, they have worked notably in infectious diseases, immunology, materials chemistry, molecular biology, and virology.

The scientist's work covers a range of topics, including:

  • HIV research and treatment
  • SARS-CoV-2 and COVID-19 research
  • COVID-19 clinical research studies
  • Immunotherapy and immune responses
  • Vaccines and immunoinformatics approaches
  • Immune cell function and interaction
  • T-cell and B-cell immunology

Shixia Wang has published extensively in the following venues:

  • Emerging Microbes & Infections
  • The Journal of Immunology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • SSRN Electronic Journal
  • The Journal of Infectious Diseases

Notable recent papers by Shixia Wang include:

  • "A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2," 2022, Emerging Microbes & Infections
  • "Mathematic modeling of COVID-19 in the United States," 2020, Emerging Microbes & Infections
  • "A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques," 2021, Emerging Microbes & Infections
  • "High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster," 2022, The Journal of Infectious Diseases
  • "Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice," 2022, PLoS Pathogens

The scientist frequently collaborates with other researchers, including Shan Lu, Guangnan Hu, Alexander Rumyantsev, Thomas P. Monath, and Brett A. Thibodeaux. These coauthors have been involved in multiple projects alongside Wang, indicating sustained collaborative efforts.

Best Publications

  • The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region

    S. W. Barnett;S. Lu;I. Srivastava;S. Cherpelis

  • Effect of vaccine administration modality on immunogenicity and efficacy.

    Lu Zhang;Wei Wang;Shixia Wang

  • Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers

    Shixia Wang;Jeffrey S. Kennedy;Kim West;David C. Montefiori

  • Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants

    Robyn Marty-Roix;Gregory I. Vladimer;Kimberly Pouliot;Dan Weng

  • The wide utility of rabbits as models of human diseases

    Pedro J. Esteves;Joana Abrantes;Hanna Mari Baldauf;Lbachir BenMohamed

  • Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E

    Shixia Wang;Ranajit Pal;John R. Mascola;Te-Hui W. Chou

  • Current progress of DNA vaccine studies in humans.

    Shan Lu;Shixia Wang;Jill M Grimes-Serrano

  • EV71: An emerging infectious disease vaccine target in the Far East?

    Juan Xu;Yuan Qian;Shixia Wang;Shixia Wang;Jill M. Grimes Serrano

  • Follicular regulatory T cells repress cytokine production by follicular helper T cells and optimize IgG responses in mice.

    Hao Wu;Yuxin Chen;Hong Liu;Lin Lin Xu

  • Hemagglutinin (HA) Proteins from H1 and H3 Serotypes of Influenza A Viruses Require Different Antigen Designs for the Induction of Optimal Protective Antibody Responses as Studied by Codon-Optimized HA DNA Vaccines

    Shixia Wang;Jessica Taaffe;Christopher S. Parker;Alicia Solorzano

  • Protection Against Rotavirus Infections By DNA Vaccination

    John E. Herrmann;Shing C. Chen;Ellen F. Fynan;Joseph C. Santoro

  • Enhanced Immunogenicity of gp120 Protein When Combined with Recombinant DNA Priming To Generate Antibodies That Neutralize the JR-FL Primary Isolate of Human Immunodeficiency Virus Type 1

    Shixia Wang;James Arthos;John M. Lawrence;Donald I. Van Ryk

  • Improved Induction of Antibodies against Key Neutralizing Epitopes by Human Immunodeficiency Virus Type 1 gp120 DNA Prime-Protein Boost Vaccination Compared to gp120 Protein-Only Vaccination

    Michael Vaine;Shixia Wang;Emma T. Crooks;Pengfei Jiang

  • Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

    Ranajit Pal;Shixia Wang;V.S. Kalyanaraman;B.C. Nair

  • Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine.

    Shixia Wang;Diego J. Farfan-Arribas;Siyuan Shen;Te-hui W. Chou

  • The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods

    Shixia Wang;Chunghua Zhang;Lu Zhang;Jun Li

  • Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

    Michael Vaine;Shixia Wang;Anthony Hackett;James Arthos

  • Heterologous HA DNA vaccine prime - inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses

    Shixia Wang;Chris Parker;Jessica Taaffe;Alicia Solórzano

  • Increased Immunogenicity of Human Immunodeficiency Virus gp120 Engineered To Express Galα1-3Galβ1-4GlcNAc-R Epitopes

    Ussama M. Abdel-Motal;Shixia Wang;Shan Lu;Kim Wigglesworth

  • Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.

    Shan Lu;Richard T. Wyatt;Joan F. L. Richmond;Farah Mustafa

Frequent Co-Authors

Shan Lu
Shan Lu University of Massachusetts Chan Medical School
Susan Zolla-Pazner
Susan Zolla-Pazner Icahn School of Medicine at Mount Sinai
David C. Montefiori
David C. Montefiori Duke University
Miroslaw K. Gorny
Miroslaw K. Gorny New York University
Phillip D. Markham
Phillip D. Markham Northrop Grumman (United States)
Vaniambadi S. Kalyanaraman
Vaniambadi S. Kalyanaraman North Shore University Hospital
James Arthos
James Arthos National Institute of Allergy and Infectious Diseases
Egil Lien
Egil Lien University of Massachusetts Chan Medical School
Ranajit Pal
Ranajit Pal Advanced Bioscience Laboratories (United States)
Paul R. Clapham
Paul R. Clapham University of Massachusetts Chan Medical School

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare roles can open various career opportunities. Advanced nursing degrees, such as becoming a Psychiatric Mental Health Nurse Practitioner, offer specialized care options closely tied to immune system health. Prospective students can find programs with strong clinical experience by reviewing the best online psychiatric mental health nurse practitioner programs.

Cost is often a deciding factor when selecting a degree path. Those seeking budget-friendly education options should consider checking out the cheap psych np programs, which provide affordable routes without compromising quality.

Understanding salary expectations is crucial for long-term planning. Salaries for nurse practitioners, including those with Doctor of Nursing Practice degrees, vary by state and specialization. Detailed insights can be found by exploring the dnp salary data.

Additionally, for current Family Nurse Practitioners considering career growth, transitioning into more acute care roles can enhance clinical expertise. Relevant guidance and program options are available in resources about acute care nurse practitioner programs.

Best Scientists Citing Shixia Wang

Trending Scientists

Recently Published Articles